A- A A+
Last Updated : Nov 28 2020 10:51AM     Screen Reader Access
News Highlights
PM to visit Ahmedabad, Hyderabad & Pune today to review COVID-19 vaccine development & manufacturing process            J&K: Polling begins for 1st phase of DDC elections & Panchayat by-polls            GDP Estimates of 2nd quarter more encouraging than anticipated, says Chief Economic Advisor            PM Modi speaks to Tamil Nadu CM; Central teams being rushed to state to assist in rescue & relief work in wake of Cyclone Nivar            India, United Kingdom look forward to enhance cooperation & partnership in post-COVID and post-BREXIT era           

International News

Nov 20, 2020
8:37PM

Oxford-AstraZeneca vaccine shows strong immune response in elderly

AIR
The Oxford-AstraZeneca Covid-19 vaccine candidate shows a strong immune response in adults in their 60s and 70s, according to researchers, raising hopes that it can protect age groups most at risk from the virus.

Researchers say the Lancet phase two findings, based on 560 healthy adult volunteers, are encouraging.

Three vaccines - Pfizer-BioNTech, Sputnik and Moderna - have already reported good preliminary data from phase three trials, with one suggesting 94% of people over 65 could be protected from Covid-19.

Older people's weaker immune systems generally mean vaccines do not tend to function as well as they do in younger people. But, these trial results from the University of Oxford, peer-reviewed in the Lancet, suggest that may not be a problem. They show that older adults aged 56-69 and over 70 had a similar immune response to younger adults aged 18-55.

Dr Maheshi Ramasamy, an investigator at the Oxford Vaccine Group, said two weeks after the second dose, more than 99% of participants of all ages had neutralising antibody responses.

The T-cell response - another measure of how well the immune system responds - peaked two weeks after the first dose of the vaccine, regardless of age.

The robust antibody and T-cell responses seen in older people in the study are encouraging, Dr Ramasamy said.  The populations at greatest risk of serious Covid-19 disease include people with existing health conditions and older adults and hence, this vaccine may help to protect some of the most vulnerable people in society, he said.

   Related News

Live Twitter Feed

Listen News

Morning News 28 (Nov) Midday News 27 (Nov) Evening News 27 (Nov) Hourly 28 (Nov) (1010hrs)
समाचार प्रभात 28 (Nov) दोपहर समाचार 27 (Nov) समाचार संध्या 27 (Nov) प्रति घंटा समाचार 28 (Nov) (1000hrs)
Khabarnama (Mor) 28 (Nov) Khabrein(Day) 27 (Nov) Khabrein(Eve) 27 (Nov)
Aaj Savere 28 (Nov) Parikrama 27 (Nov)

Listen Programs

Market Mantra 27 (Nov) Samayki 9 (Aug) Sports Scan 27 (Nov) Spotlight/News Analysis 27 (Nov) Employment News 27 (Nov) World News 27 (Nov) Samachar Darshan 22 (Mar) Radio Newsreel 21 (Mar)
    Public Speak

    Country wide 12 (Mar) Surkhiyon Mein 27 (Nov) Charcha Ka Vishai Ha 11 (Mar) Vaad-Samvaad 17 (Mar) Money Talk 17 (Mar) Current Affairs 6 (Mar) Sanskrit Saptahiki 21 (Nov) North East Diary 26 (Nov)